[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644230":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":24,"locations":32,"responsibleParty":45,"collaborators":12,"id":47,"slug":12,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":12,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":12,"enrollmentInfo":55,"targetDuration":12,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":72,"overallStatus":79,"whyStopped":12,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Christiana Care Health Services","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Control","NO_INTERVENTION","No additional intervention",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Cyclobenzaprine","EXPERIMENTAL","5mg cyclobenzaprine q8h for one week postoperatively",[18],"Drug: Cyclobenzaprine",[20],{"type":21,"name":14,"description":22,"armGroupLabels":23,"otherNames":12},"DRUG","5mg cyclobenzaprine q8hr for one week postoperatively after minimally invasive hysterectomy",[14],[25,30],{"name":26,"role":27,"phone":28,"phoneExt":12,"email":29},"Margaret Wingo, MD","CONTACT","302-623-4410","margaret.wingo@christianacare.org",{"name":31,"role":27,"phone":12,"phoneExt":12,"email":12},"Kathryn Denny, MD",[33],{"facility":34,"status":12,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":12},"ChristianaCare Health System","Newark","Delaware","19718","United States",{"type":40,"coordinates":41},"Point",[42,43],-75.74966,39.68372,{"lat":43,"lon":42},{"type":46,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100644230",false,"NCT07664956","Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy","Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age \\>18yo\n* Female\n* English speaking\n* Undergoing (robotic assisted or classic) total laparoscopic hysterectomy ± unilateral or bilateral salpingectomy ± unilateral or bilateral oophorectomy\n* If other procedures such as lysis of adhesions, excision of endometriosis, or ureterolysis are indicated based on intraoperative evaluation, those patients may still be included\n* Surgery took place at ChristianaCare Hospitals\n* No allergies or contraindications to standard of care post operative pain medications (acetaminophen, NSAIDs, narcotics) or cyclobenzaprine\n\nExclusion Criteria:\n\n* Age \\\u003C18yo\n* Male\n* Pregnant, breastfeeding\n* Non-English speaking\n* Primary procedures other than laparoscopic hysterectomy\n* Laparoscopic myomectomy\n* Laparoscopic resection of endometriosis\n* Laparoscopic unilateral or bilateral salpingectomy ± unilateral or bilateral oophorectomy ± unilateral or bilateral cystectomy without hysterectomy\n* Hysteroscopic procedures\n* Bartholin gland marsupialization\n* Operations that are scheduled as or converted to the open approach\n* Procedures with planned or unplanned bladder or bowel surgery\n* Allergies or contraindications to standard post operative pain control medications (acetaminophen, NSAIDs, narcotics), such as kidney or liver damage\u002Ffailure, bariatric surgery, history of gastric ulcer, etc.\n* Chronic pain issues, whether self-diagnosed or by a physician, currently undergoing management\n* Currently undergoing medication assisted treatment for opioid use disorder\n* Currently using opioids consistently\n* Allergies or contraindications to cyclobenzaprine:\n* Absolute: use of MAO inhibitors within 14 days, recent heart attack, congestive heart failure, heart block or other conduction abnormalities, cardiac arrhythmias, hyperthyroidism, history of serotonin syndrome\n* Allergies or contraindications to inactive ingredients in Flexeril, such as lactose\n* Patient's receiving gabapentin at baseline or postoperatively, due to potential sedating effects, or other sedating drugs such as scheduled benzodiazepines and barbiturates","FEMALE","18 Years",{"count":56,"type":57},36,"ESTIMATED","INTERVENTIONAL",[60],"PHASE4","Typical postoperative pain control after minimally invasive hysterectomy includes ibuprofen, acetaminophen, and a short course of narcotics. The purpose of this study is to see if adding cyclobenzaprine to this regime improves pain control and lessens narcotic use.",[63,64,65,66,67,68,69,70,71],"Minimally Invasive Surgical Procedures","Abnormal Uterine Bleeding, Unspecified","Adenomyosis of Uterus","Fibroid Uterus","Chronic Pelvic Pain","Endometriosis","Menorrhagia","Endometritis","Adnexal Diseases",[73,74,75,76,77,78],"cyclobenzaprine","flexeril","hysterectomy","minimally invasive hysterectomy","pain control","multimodal pain control","NOT_YET_RECRUITING","2026-06-18",{"date":82,"type":83},"2026-06-24","ACTUAL",{"date":85,"type":57},"2026-07-01",{"date":87,"type":57},"2026-12-01",{"name":5,"class":6},1]